Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
Not Confirmed
Not Confirmed
30 September-02 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Industry Trade Show
Not Confirmed
30 September-02 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
24 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/24/2952609/0/en/Kairos-Pharma-Enters-Agreement-with-PreCheck-Health-Services-to-Develop-Biomarkers-to-Identify-Patients-Responsive-to-ENV105-to-Target-Cancer-Drug-Resistance-in-Prostate-and-Lung-C.html
17 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/17/2947841/0/en/Kairos-Pharma-Closing-of-6-2-Million-Initial-Public-Offering.html
17 Sep 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/kairos-goes-public-6m-ipo-fund-trials-lead-cancer-drug
16 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/16/2946812/0/en/Kairos-Pharma-Prices-6-2-Million-Initial-Public-Offering.html
30 Jan 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/01/30/2820140/0/en/Kairos-Pharma-Doses-First-Patient-in-Phase-2-Trial-of-Lead-Drug-Candidate-ENV105-with-Apalutamide-to-Improve-Therapy-Sensitivity-for-Castrate-Resistant-Prostate-Cancer.html
16 Jan 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/01/16/2810031/0/en/Kairos-Pharma-Doses-First-Patients-in-Phase-1-Trial-of-Lead-Drug-Candidate-ENV105-with-Osimertinib-to-Improve-Therapy-Sensitivity-for-EGFR-Driven-Lung-Cancer.html
Details:
ENV105 (carotuximab) is a endoglin inhibitor which is being evaluated in phase 2 clinical trials in combination with apalutamide for the treatment of castrate-resistant prostate cancer.
Lead Product(s): Carotuximab,Apalutamide
Therapeutic Area: Oncology Brand Name: ENV105
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Lead Product(s) : Carotuximab,Apalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ENV105 (carotuximab) is a endoglin inhibitor which is being evaluated in phase 2 clinical trials in combination with apalutamide for the treatment of castrate-resistant prostate cancer.
Brand Name : ENV105
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 30, 2024
Details:
ENV105 (carotuximab) is a novel ENG inhibitor monoclonal antibody. It is currently being evaluated in phase 1 clinical trials in combination with osimertinib for the treatment of non-small cell lung cancer.
Lead Product(s): Carotuximab,Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: ENV105
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Lead Product(s) : Carotuximab,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ENV105 (carotuximab) is a novel ENG inhibitor monoclonal antibody. It is currently being evaluated in phase 1 clinical trials in combination with osimertinib for the treatment of non-small cell lung cancer.
Brand Name : ENV105
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 16, 2024
Details:
KROS 201 activated T cells, are killer T cells that are developed in cell culture by activating a patient's white blood cells with cytokines or T cell activating signals and by priming dendritic cells loaded with glioblastoma cancer stem cell-specific antigens.
Lead Product(s): KROS-201
Therapeutic Area: Oncology Brand Name: KROS-201
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Lead Product(s) : KROS-201
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KROS 201 activated T cells, are killer T cells that are developed in cell culture by activating a patient's white blood cells with cytokines or T cell activating signals and by priming dendritic cells loaded with glioblastoma cancer stem cell-specific an...
Brand Name : KROS-201
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 14, 2022
Details:
ENV105 has been demonstrated to complement standard of care androgen targeted therapy with non-steroidal anti-androgens such as XTANDI® (enzalutamide) and Zytiga® (abiraterone acetate) in limiting therapeutic resistance to these drugs in a previous Phase II trial.
Lead Product(s): ENV-105,Apalutamide
Therapeutic Area: Oncology Brand Name: ENV-105
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Lead Product(s) : ENV-105,Apalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ENV105 has been demonstrated to complement standard of care androgen targeted therapy with non-steroidal anti-androgens such as XTANDI® (enzalutamide) and Zytiga® (abiraterone acetate) in limiting therapeutic resistance to these drugs in a previous Pha...
Brand Name : ENV-105
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 15, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?